Skip to main navigation menu Skip to main content Skip to site footer

Original article

Vol. 145 No. 0506 (2015)

Impact of local vascular lesions assessed with optical coherence tomography and ablation points on blood pressure reduction after renal denervation

  • Jelena-Rima Ghadri
  • Roman Gaehwiler
  • Milosz Jaguszewski
  • Isabella Sudano
  • Julia Osipova
  • Renate Schoenenberger-Berzins
  • Paul Erne
  • Thomas F. Lüscher
  • Christian Templin
Cite this as:
Swiss Med Wkly. 2015;145:w14102


Local vascular injury is detectable with optical coherence tomography (OCT) after catheter-based renal denervation (RDN). However, it is unclear whether the number and type of vascular lesions or the number of ablation points could affect blood pressure (BP) reduction.

The aim of the study was to assess the impact of vascular injury induced by RDN detected with OCT and the number of ablation points on BP response after 1, 3 and 6 months.

METHODS: RDN was either performed with a Simplicity® catheter or an EnligHTNTM multielectrode basket followed by OCT. BP was recorded prospectively as office measurement and 24-hour ambulatory blood pressure monitoring (24-h ABPM) at each time point. Correlations between type and number of vascular lesions, as well as ablation points, on BP reduction were performed.

RESULTS: Out of 16 patients, two were lost to BP follow-up. We documented a BP reduction at 1, 3 and 6 months in both office and 24-h ABPM. The Δmean office systolic BP (SBP) reduction was –18.75 ± 24.55 mm Hg, –20.58 ± 16.92 mm Hg and –18.75 ± 29.39 mm Hg, respectively, and the Δmean 24h-ABPM SBP reduction was –6.50 ± 23.45 mm Hg, –16.88 ± 26.64 mm Hg and –13.89 ± 21.20 mm Hg, respectively. The number of vascular lesions did not correlate with office and 24h-SBP and diastolic BP reduction. However, there was a correlation between ablation points and office Δmean SBP reduction at 6 months (p <0.02).

CONCLUSIONS: Our study demonstrates for the first time that the number and type of vascular lesions as assessed with OCT did not predict the success of BP reduction after RDN. However, we observed a substantial decrease in office SBP in relation to the number of ablation points at 6 months.


  1. Symplicity HTNI, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903–9.
  2. Bunte MC, Infante de Oliveira E, Shishehbor MH. Endovascular treatment of resistant and uncontrolled hypertension: therapies on the horizon. JACC Cardiovasc Interv. 2013;6:1–9.
  3. Mahfoud F, Ukena C, Schmieder RE, Cremers B, Rump LC, Vonend O, et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation. 2013;128:132–40.
  4. Mahfoud F, Lüscher TF, Andersson B, Baumgartner I, Cifkova R, Dimario C, et al. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J. 2013;34:2149–57.
  5. Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, et al. and Investigators SH-. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393–401.
  6. Templin C, Jaguszewski M, Ghadri JR, Sudano I, Gaehwiler R, Hellermann JP, et al. Vascular lesions induced by renal nerve ablation as assessed by optical coherence tomography: pre- and post-procedural comparison with the Simplicity (R) catheter system and the EnligHTN (TM) multi-electrode renal denervation catheter. Eur Heart J. 2013;34:2141–8.
  7. Jaguszewski M, Ghadri JR, Lüscher TF, Templin C. Optical coherence tomography to reveal vascular lesions after catheter-based renal nerve ablation with a novel multi-electrode EnligHTN system. Kardiol Pol. 2013;71:775.
  8. Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W, et al. Optical coherence tomography. Science. 1991;254:1178–81.
  9. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275–81.
  10. Esler MD, Krum H, Schlaich M, Schmieder RE, Bohm M, Sobotka PA. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation. 2012;126:2976–82.
  11. Ott C, Mahfoud F, Schmid A, Ditting T, Sobotka PA, Veelken R, et al. Renal denervation in moderate treatment-resistant hypertension. J Am Coll Cardiol. 2013;62:1880–6.
  12. Lüscher TF, Mahfoud F. Renal nerve ablation after SYMPLICITY HTN-3: confused at the higher level? Eur Heart J. 2014;35:1706–11.
  13. Dorr O, Liebetrau C, Mollmann H, Achenbach S, Sedding D, Szardien S, et al. Renal sympathetic denervation does not aggravate functional or structural renal damage. J Am Coll Cardiol. 2013;61:479–80.
  14. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911–7.
  15. Schlaich MP, Schmieder RE, Bakris G, Blankestijn PJ, Bohm M, Campese VM, et al. International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol. 2013;62:2031–45.
  16. Mahfoud F, Cremers B, Janker J, Link B, Vonend O, Ukena C, et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension. 2012;60:419–24.
  17. Hering D, Mahfoud F, Walton AS, Krum H, Lambert GW, Lambert EA, et al. Renal denervation in moderate to severe CKD. J Am Soc Nephrol. 2012;23:1250–7.
  18. Ukena C, Mahfoud F, Kindermann I, Barth C, Lenski M, Kindermann M, et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. J Am Coll Cardiol. 2011;58:1176–82.
  19. Ott C, Janka R, Schmid A, Titze S, Ditting T, Sobotka PA, et al. Vascular and renal hemodynamic changes after renal denervation. Clin J Am Soc Nephrol. 2013;8:1195–201.
  20. Ormiston JA, Watson T, van Pelt N, Stewart R, Stewart JT, White JM, et al. Renal denervation for resistant hypertension using an irrigated radiofrequency balloon: 12–month results from the Renal Hypertension Ablation System (RHAS) trial. EuroIntervention. 2013;9:70–4.
  21. Worthley SG, Tsioufis CP, Worthley MI, Sinhal A, Chew DP, Meredith IT, et al. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J. 2013;34:2132–40.
  22. Steigerwald K, Titova A, Malle C, Kennerknecht E, Jilek C, Hausleiter J, et al. Morphological assessment of renal arteries after radiofrequency catheter-based sympathetic denervation in a porcine model. J Hypertens. 2012;30:2230–9.
  23. Stabile E, Ambrosini V, Squarcia R, Salemme L, Popusoi G, Esposito G, et al. Percutaneous sympathectomy of the renal arteries: the OneShot Renal Denervation System is not associated with significant vessel wall injury. EuroIntervention. 2013;9:694–9.
  24. Vogel B, Kirchberger M, Zeier M, Stoll F, Meder B, Saure D, et al. Renal sympathetic denervation therapy in the real world: results from the Heidelberg registry. Clinical research in cardiology: official journal of the German Cardiac Society. 2014;103:117–24.
  25. Prati F, Guagliumi G, Mintz GS, Costa M, Regar E, Akasaka T, et al. and Expert’s OCTRD. Expert review document part 2: methodology, terminology and clinical applications of optical coherence tomography for the assessment of interventional procedures. Eur Heart J. 2012;33:2513–20.

Most read articles by the same author(s)

1 2 3 > >>